Prokidney reports third quarter 2024 financial results along with regulatory and clinical development updates following successful fda type b meeting

Winston-salem, n.c., nov. 12, 2024 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today reported financial results for the third quarter ended september 30, 2024, and gave several regulatory and clinical development updates.
PROK Ratings Summary
PROK Quant Ranking